Avail adopts pharma’s strategy – and pharma business strategist

As American federal regulators get tougher on flavours, and brands such as Juul are two-stepping to avoid the proverbial stick, companies like Avail Vapor see a way of making tough regulation work in their favour.

Avail has just hired a former strategist from the pharmaceutical world for the newly minted post of director of business development for its contract manufacturing services.

“Avail took a step back and was looking at how they’re going to succeed in the industry,” Brooks Gordon told ECigIntelligence about the creation of his role with the company.

He said the executives who brought him to Avail wanted someone with experience in sales and strategy – and pharmaceutical industry experience in dealing with the US Food and Drug Administration (FDA).

Read full article
I'm already a subscriber
Author default picture

Daniel Mollenkamp

Our Key Benefits

The global e-cigarette market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

ECigIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization